

The June 10, 2021, article by Moore et al entitled “Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)” (*J Clin Oncol* 10.1200/JCO.21.00306) was published with an error.

In the author list, the affiliation for the third author, Jalid Sehouli, MD, read as:

⁴Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (North-Eastern German Society of Gynaecologic Oncology; NOGGO), Berlin, Germany and Charité-Medical University of Berlin (Campus Virchow Klinikum), Berlin, Germany

It should have read as:

⁴Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe (AGO-Study Group) + Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (North-Eastern German Society of Gynaecologic Oncology; NOGGO), Germany and Charité-Medical University of Berlin (Campus Virchow Klinikum), Berlin, Germany

This has been corrected as of June 14, 2021. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.21.01441>

ASCO® Meetings

ASCO offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide.

View upcoming meetings and symposia at meetings.asco.org